Last reviewed · How we verify
muscular aches — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Excedrin Extra Strength Pain Reliever | NSAID | Haleon Us Holdings | Nonsteroidal Anti-inflammatory Drug [EPC] | Cyclooxygenase | 2004-01-01 | |
| MEDIQUE APAP EXTRA STRENGTH acetaminophen tablet, film coated | APAP | HF Acquisition Co LLC, DBA HealthFirst |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- HF Acquisition Co LLC, DBA HealthFirst · 1 drug in muscular aches
- Haleon Us Holdings · 1 drug in muscular aches
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in muscular aches:
- muscular aches treatment updates — RSS
- muscular aches treatment updates — Atom
- muscular aches treatment updates — JSON
Cite this brief
Drug Landscape (2026). muscular aches — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/muscular-aches. Accessed 2026-06-10.
Related
- muscular aches full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing